CONTACTStaffCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2023 Pride Publishing Inc.
All Rights reserved
All Rights reserved
Don’t miss our latest news! Sign up today for our free newsletter.
Scroll To Top
By continuing to use our site, you agree to our Private Policy and Terms of Use.
GlaxoSmithKline said on Thursday that U.S. regulators have approved the use of its drug Hycamtin in combination with cisplatin for the treatment of cervical cancer that can't be treated with surgery or radiation therapy. The Food and Drug Administration approval is based on late-stage results that demonstrated a survival advantage by using Hycamtin in combination with cisplatin compared with cisplatin alone. The company is currently developing a vaccine for the human papilloma virus, the leading cause of cervical cancer. Hycamtin is currently marketed in the United States for the treatment of a type of lung cancer. (Reuters)
Want more breaking equality news & trending entertainment stories?
Check out our NEW 24/7 streaming service: the Advocate Channel!
Download the Advocate Channel App for your mobile phone and your favorite streaming device!
From our Sponsors
Most Popular
Lauren Boebert Caught Fondling Date’s Genitals During Family-Friendly Musical: Video
September 15 2023 11:20 PM
Don’t miss our latest news! Sign up today for our free newsletter.
Watch Now: Advocate Channel
Trending Stories & News
For more news and videos on advocatechannel.com, click here.
Trending Stories & News
For more news and videos on advocatechannel.com, click here.
Latest Stories
How Jonathan Van Ness Clapped Back at Megyn Kelly Over Mocking Trans Inclusion in Sports
September 28 2023 6:34 PM
Lauren Boebert Under Fire for Horrifying Transphobic Comments About Pentagon Official
September 28 2023 6:14 PM
Weatherman Erick Adame Opens Up About Exposing Himself Online, His Firing, and His Future
September 28 2023 4:26 PM
Sylvia Swayne Aims to Make History as Alabama’s First Trans State Representative
September 28 2023 1:00 PM